These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 15785088)
21. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3. Okuda H; Saito A; Shiratori K; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2005 May; 20(5):759-64. PubMed ID: 15853991 [TBL] [Abstract][Full Text] [Related]
22. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526 [TBL] [Abstract][Full Text] [Related]
23. [Tumor markers of hepatocellular carcinoma]. Kubo S; Matsukawa M Gan To Kagaku Ryoho; 2004 Dec; 31(13):2203-6. PubMed ID: 15628773 [TBL] [Abstract][Full Text] [Related]
24. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Matsushima-Nishiwaki R; Okuno M; Takano Y; Kojima S; Friedman SL; Moriwaki H Carcinogenesis; 2003 Aug; 24(8):1353-9. PubMed ID: 12807734 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346 [TBL] [Abstract][Full Text] [Related]
26. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Fujioka M; Nakashima Y; Nakashima O; Kojiro M Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002 [TBL] [Abstract][Full Text] [Related]
27. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Yoshida S; Kurokohchi K; Arima K; Masaki T; Hosomi N; Funaki T; Murota M; Kita Y; Watanabe S; Kuriyama S Int J Oncol; 2002 Feb; 20(2):305-9. PubMed ID: 11788893 [TBL] [Abstract][Full Text] [Related]
28. [Studies on the mechanism of elevation of serum PIVKA-II levels in alcoholic liver cirrhosis]. Sakizono K; Oita T; Eto M; Bito S; Takegawa H; Kasakura S Rinsho Byori; 2002 Mar; 50(3):289-95. PubMed ID: 11985059 [TBL] [Abstract][Full Text] [Related]
29. [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection]. Matsushita A; Hanazaki K; Noike T; Nakagawa K; Misawa R; Nakata T; Nomura K; Kobayashi A; Miwa S; Miyagawa S; Kawasaki S Gan To Kagaku Ryoho; 2003 Sep; 30(9):1327-32. PubMed ID: 14518415 [TBL] [Abstract][Full Text] [Related]
30. [Clinical usefulness of lectin-reactive fraction of alpha-fetoprotein in hepatocellular carcinoma]. Tamura A; Oita T; Sakizono K; Nakajima T; Kasakura S Rinsho Byori; 1998 Feb; 46(2):158-62. PubMed ID: 9528340 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698 [TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma]. Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968 [TBL] [Abstract][Full Text] [Related]
34. Are both PIVKA-II and alpha-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma? Koh T; Taniguchi H; Katoh H; Kunishima S; Yamaguchi A; Yamagishi H Hepatogastroenterology; 2002; 49(48):1615-8. PubMed ID: 12397748 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271 [TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199 [TBL] [Abstract][Full Text] [Related]
37. Polyprenoic acid in hepatocellular carcinoma. Decensi A; Costa A N Engl J Med; 1996 Nov; 335(19):1461; author reply 1461-2. PubMed ID: 8927082 [No Abstract] [Full Text] [Related]
38. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961 [TBL] [Abstract][Full Text] [Related]
39. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Shimizu M; Shirakami Y; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Moriwaki H Mol Nutr Food Res; 2014 Jan; 58(1):124-35. PubMed ID: 24273224 [TBL] [Abstract][Full Text] [Related]
40. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]